Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone and fitbit data may forecast COPD attacks

NCT ID NCT06118632

Knowledge-focused Sponsor: Chelsea and Westminster NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study is testing whether a smartphone app and a Fitbit can detect early warning signs of a COPD flare-up. Around 300 people with COPD will be monitored for three months after leaving the hospital. The goal is to see if remote measurements of vital signs and symptoms can predict a decline in health, potentially allowing doctors to intervene early and prevent hospital readmission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Remote monitoring with a smartphone app and Fitbit device
What this could lead to
If successful, this could enable early intervention for COPD flare-ups, potentially reducing hospital readmissions and improving patient outcomes.
What could go wrong
This is an observational study, so it won't test a treatment. The technology may not reliably predict exacerbations, and data quality or patient adherence could be challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

131 people

The number who actually took part.

Started

Sep 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

COPD patients admitted in hospital

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 or over. * Diagnosis of COPD, currently admitted to hospital and clinically stable with a confirmed acute exacerbation of COPD. * Ownership of a smartphone (iOS version 13 or above, Android version 8 or above). * Able to provide informed consent to participate in study. Exclusion Criteria: * Patients who require less than 24 hours in hospital at initial visit. * Patients deemed unlikely to cooperate with study requirements. * Patients with implantable devices. * Patient not felt to be suitable for research enrolment by admitting clinical team. * Patients requiring non-invasive ventilation or deemed to have a life-expectancy of less than 90 days following discharge.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD exacerbation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD exacerbation

Contacts and locations

Locations

  • Chelsea and Westminster Hospital

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.